Developments in the treatment of leishmaniasis and trypanosomiasis

Expert Opinion on Emerging Drugs

Volumn 7, Issue 1, 2002, Pages 61-67

  Olliaro, Piero ^a   Lazdins, Janis ^a   Guhl, Felipe ^a  

^a WORLD BANK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 5 (1 METHYL 5 NITRO 2 IMIDAZOLYL) 1,3,4 THIADIAZOLE; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ANTITRYPANOSOMAL AGENT; CRUZIPAIN; CRUZIPAIN INHIBITOR; DB 289; DIMINAZENE ACETURATE; EFLORNITHINE; ENZYME INHIBITOR; MILTEFOSINE; NIFURTIMOX; PAROMOMYCIN; POSACONAZOLE; PX 6518; PYRROLE DERIVATIVE; SITAMAQUINE; TRIAZINE DERIVATIVE; TRYBIZINE; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; ANEMIA; BONE PAIN; CARDIOTOXICITY; CHAGAS DISEASE; CHILL; DRUG EFFICACY; DRUG TOLERABILITY; FEVER; HUMAN; HYPOKALEMIA; KIDNEY DYSFUNCTION; LEISHMANIASIS; REVIEW; TERATOGENICITY; TRYPANOSOMA CRUZI; TRYPANOSOMA GAMBIENSE; TRYPANOSOMA RHODESIENSE; TRYPANOSOMIASIS;

EID: 0036079502     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.7.1.61     Document Type: Review

References (16)

1. Human leishmaniases: Epidemiology and public health aspects
2. Interruption of Chagas disease transmission through vector elimination
3. Clinical and epidemiological aspects of Chagas disease
4. Practical guide for the treatment of leishmaniasis
5. Leishmaniasis
6. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection
7. Parasite genome initiatives
8. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India
9. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis
10. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis
11. Phase 2 trial of WR 6026, an orally adminstered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania Chagasi
12. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries
13. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts
14. The major cysteine proteinase of Trypanosoma cruzi: A valid target for chemotherapy of Chagas disease